



HAL
open science

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study

Stefan Schreiber, Ian C Lawrance, Ole Ø Thomsen, Stephen B. Hanauer,
Ralph Bloomfield, William J. Sandborn

► To cite this version:

Stefan Schreiber, Ian C Lawrance, Ole Ø Thomsen, Stephen B. Hanauer, Ralph Bloomfield, et al.. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. *Alimentary Pharmacology and Therapeutics*, 2010, 33 (2), pp.185. 10.1111/j.1365-2036.2010.04509.x . hal-00599493

HAL Id: hal-00599493

<https://hal.science/hal-00599493>

Submitted on 10 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Randomised clinical trial: certolizumab pegol for fistulas in
Crohn's disease – subgroup results from a placebo-
controlled study**

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0562-2010.R2
Wiley - Manuscript type:	Clinical Trial
Date Submitted by the Author:	21-Oct-2010
Complete List of Authors:	Schreiber, Stefan Lawrance, Ian Thomsen, Ole Hanauer, Stephen Bloomfield, Ralph Sandborn, William; Mayo Clinic
Keywords:	Crohn's disease < Disease-based, Inflammatory bowel disease < Disease-based, Biologics (IBD) < Topics, X keyword = no topic

1
2
3
4 **RANDOMISED CLINICAL TRIAL: CERTOLIZUMAB PEGOL FOR FISTULAS IN**
5
6 **CROHN'S DISEASE – SUBGROUP RESULTS FROM A PLACEBO-**
7
8 **CONTROLLED STUDY**
9

10
11
12
13 STEFAN SCHREIBER*, IAN C. LAWRENCE[†], OLE Ø. THOMSEN[‡], STEPHEN B.
14 HANAUER[§], RALPH BLOOMFIELD[□] & WILLIAM J. SANDBORN[¶]
15
16
17

18
19 *Department of Medicine I, Christian Albrechts University, University Hospital
20 Schleswig-Holstein, Kiel, Germany, [†]School of Medicine and Pharmacology, Centre
21 for Inflammatory Bowel Diseases, University of Western Australia, Fremantle
22 Hospital, Fremantle, Australia; [‡]Department of Gastroenterology, Herlev Hospital,
23 University of Copenhagen, Denmark; [§] Section of Gastroenterology, Hepatology and
24 Nutrition, University of Chicago Hospital Center, Chicago, IL, USA; [□]UCB Pharma,
25 Slough, UK; [¶]Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester,
26 MN, USA
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Correspondence to:

Stefan Schreiber, MD
Department of Medicine
Christian-Albrechts-Universität Kiel
Schittenhelmstr. 12, 24105 Kiel
Germany
E-mail: s.schreiber@mucosa.de

Running title: Certolizumab pegol for the treatment of fistulas

SUMMARY

Background: Background: Treatment options for fistulizing Crohn's disease (CD) are limited.

Aims: To examine whether fistula closure is maintained at week 26 following treatment with certolizumab pegol (CZP).

Methods: Patients with draining fistulas at baseline from PRECiSE 2 (n =108) received open-label induction with CZP 400 mg at weeks 0 (baseline), 2 and 4. Response was defined as ≥ 100 -point decrease from baseline in the Crohn's Disease Activity Index. Nonresponders (50/108) were excluded. At week 6, responders with draining fistulas (N = 58) were randomized to CZP 400 mg (n = 28) or placebo (n = 30) every 4 weeks across weeks 8–24. Fistula closure was evaluated throughout the study, with a final assessment at week 26.

Results: The majority of patients (55/58) had perianal fistula. At week 26, 36% of patients in the CZP group had 100% fistula closure compared with 17% of patients receiving placebo (P = 0.038).

Protocol-defined fistula closure ($\geq 50\%$ closure at two consecutive post-baseline visits ≥ 3 weeks apart) was not statistically significant (P = 0.069) with 54% and 43% of patients treated with CZP and placebo achieving this endpoint, respectively.

Conclusion: Continuous treatment with CZP improves the likelihood of sustained perianal fistula closure compared with placebo.

INTRODUCTION

Development of fistulas occurs frequently in patients with Crohn's disease (CD). A population-based study demonstrated that after 10 years of disease the cumulative risk for developing fistulas is 33%, and this increases to 50% after 20 years.^{1,2} Perianal fistula is the most common fistula type; it occurs in 25–50% of patients with CD³ and often causes severe impairment in their quality of life.⁴

Treatment options for fistulas are limited.^{5,6} Until recently, surgery has been the mainstay for treating fistulas; however, invasive surgical treatments such as extensive dissection can lead to incontinence in some patients.³ In addition, while corticosteroids have potent anti-inflammatory actions and are effective in the treatment of luminal CD, they have not been demonstrated to benefit patients with fistulizing disease.⁴ Antibiotics are a widely used short-term treatment for fistulas in patients with CD; however, despite their widespread use, there are limited controlled studies demonstrating their symptomatic efficacy in patients with fistulizing CD.⁷ In an open-label case series of 21 patients with perianal CD treated with 20 mg/kg/day of metronidazole, 56% of patients had complete fistula healing and all had a positive clinical response. However, follow-up of 17 of these patients showed that when the dosage was decreased, the symptoms reappeared.⁸ Immunosuppressive agents such as azathioprine and 6-mercaptopurine have been shown to successfully treat the intestinal inflammation of CD; however, data on their ability to treat fistulas in these patients are limited. In a meta-analysis of 5 randomized, controlled trials in which closure of various fistulas (including perianal, enterocutaneous, enteroenteric, recto-vaginal and vulvar types) was a secondary end point, a beneficial effect of azathioprine and 6-mercaptopurine was shown in 54% (22 of 41) of patients compared with 21% (6 of 29) in the placebo group after 6 months of treatment (pooled odds ratio of 4.4; 95% confidence interval [CI], 1.5–13.2).⁹ The formation of a CD fistula can, therefore, be considered a difficult to treat and sometimes

1
2
3 irreversible form of structural damage as a consequence of incompletely controlled
4
5 inflammation.
6
7

8
9
10 Meta-analysis of the anti-tumour necrosis factor (TNF) agents infliximab, adalimumab and
11
12 certolizumab pegol has shown success with their use in fistulizing CD. In an overall analysis,
13
14 anti-TNF therapy was more effective than placebo for complete fistula closure.¹⁰ Detailed
15
16 reports on the efficacy of infliximab and adalimumab for closure of fistulas have been
17
18 published previously.¹¹⁻¹³
19
20

21
22
23 Limited data on the effectiveness of certolizumab pegol in the treatment of fistulas in the
24
25 PRECiSE 2 study have been published.¹⁴ In the PRECiSE 2 study, 14% of patients in the
26
27 overall population who had a response to induction therapy with certolizumab pegol and
28
29 were included in the intent-to-treat population (58 of 425) had draining fistulas (28 patients in
30
31 the certolizumab group and 30 in the placebo group). In the present study, additional post
32
33 hoc analyses were performed to further examine the fistula closure effects of certolizumab
34
35 pegol and to determine whether fistula closure observed at week 6 is maintained through to
36
37 week 26.
38
39
40
41
42

43 **METHODS**

44 **Patients**

45
46
47 The methods and results of PRECiSE 2 (Clinicaltrials.gov identifier: NCT00152425) have
48
49 been reported previously.¹⁴ Adult patients were eligible if they had at least a 3-month history
50
51 of active CD, defined as a Crohn's Disease Activity Index score of 220–450.^{14,15} **A total of**
52
53 **108 patients had** open draining fistulas at week 0. **Among these patients, 58** had a clinical
54
55 response to induction with certolizumab pegol (defined as reduction of at least 100 from the
56
57 baseline score on CDAI) at week 6. These patients ($N = 58$) were randomized to double-
58
59 blind maintenance treatment (**Figure 1**). For each patient, each individual fistula was
60

1
2
3 assessed at every visit to determine whether it was closed or not. Physicians assessed if a
4
5 fistula was closed by the absence of drainage on gentle compression.
6
7
8
9

10 Efficacy analyses

11
12 **Data are presented for the intention to treat population (N = 58).** Fistula closure was defined
13
14 as the absence of drainage on gentle compression at any two consecutive post-baseline
15
16 visits at least 3 weeks apart.¹⁴ The following efficacy variables were analyzed: 1)
17
18 assessment of fistula closure at weeks 2, 4, 6, 8, 12, 16, 20, 24 and 26 compared with week
19
20 0 (≥50% closure of fistulas open at baseline and 100% closure of fistulas open at baseline);
21
22 2) maintenance of fistula closure, defined as at least 50% closure of fistulas at any two
23
24 consecutive post-baseline visits (≥3 weeks apart) at any time during the study and at least
25
26 50% or 100% closure at week 26; 3) fistula closure based on the prespecified definition in
27
28 the PRECiSE 2 study (closure of ≥50% of fistulas at any two consecutive post-baseline visits
29
30 ≥3 weeks apart); 4) CDAI response and remission (CDAI was calculated using established
31
32 methods;¹⁵ remission was defined as a CDAI score of ≤150 points and response was
33
34 defined as a decrease from week 0 in CDAI score of ≥100 points); and 5) Inflammatory
35
36 Bowel Disease Questionnaire (IBDQ) efficacy measures. The IBDQ efficacy measure was
37
38 calculated using established methods.^{16,17} The mean increase in the IBDQ score from week
39
40 0 and the mean increase in the score of the individual domains of the IBDQ score (bowel
41
42 symptoms, systemic symptoms, emotional function, social function) from week 0 were
43
44 calculated.
45
46
47
48
49
50

51 Statistical analyses

52
53 All data presented are exploratory; nominal *P* values were calculated using logistic
54
55 regression including factors for treatment, C-reactive protein (CRP) strata at entry (<10 mg/L
56
57 / ≥ 10 mg/L), steroid use at entry, immunosuppressant use at entry and geographical region
58
59 (this was done as subjects had been stratified for these variables when randomized).
60

1
2
3 Missing data were imputed as not achieving the end point for binary outcomes. For IBDQ
4
5 efficacy measures, the last observation carried forward was imputed for continuous
6
7 outcomes.
8
9

10 11 12 **RESULTS**

13 14 15 16 **Patients**

17
18 After three induction doses of certolizumab pegol 400 mg, a total of 58 patients with draining
19
20 fistulas at baseline responded according to CDAI criteria. These 58 patients were
21
22 randomized in the double-blind phase: 28 to certolizumab pegol 400 mg q4w and 30 to
23
24 placebo q4w. Reasons for withdrawal are shown in Figure 1.
25
26
27

28
29 The demographic features of these patients are shown in Table 1. Anal fistulas were the
30
31 most common type of fistula and accounted for 95% (55 of 58) of all fistulas at baseline.
32

33 Non-anal fistulas among the placebo group ($n = 4$ patients) were recto-vaginal, posterior to
34
35 anus, left thigh, right buttock, left lateral, mid abdominal/right side, left perineum, and lower
36
37 abdomen. Non-anal fistulas in the certolizumab pegol group ($n = 3$ patients) were inguinal
38
39 right, perineal (left posterior), and left buttock. The mean number of open fistula at baseline
40
41 was 2.0 in the placebo group and 1.6 in the certolizumab pegol group.
42
43
44
45
46
47

48 **Efficacy: prespecified definition of fistula closure**

49
50 The fistula closure definition that was prespecified in the PRECiSE 2 study was closure of at
51
52 least 50% of fistulas at any two consecutive post-baseline visits at least 3 weeks apart.

53
54 Using this definition, fistula closure occurred in 54% (15 of 28) of patients randomized to
55
56 maintenance therapy with certolizumab pegol 400 mg q4w and 43% (13 of 30) randomized
57
58 to placebo ($P = 0.247$). Time to closure in both groups was similar; mean time to closure was
59
60

1
2
3 13.4 days (s.d. = 3.5) in the certolizumab pegol 400 mg group and 13.3 days (s.d. = 3.3) in
4
5 the placebo group.
6
7
8
9

10 Efficacy: 50% and 100% fistula closure at weeks 2, 4, 6, 8, 12, 16, 20, 24 and 26

11 Figure 2 shows the percentage of patients with at least 50% fistula closure (Figure 2A) and
12 the percentage of patients with 100% fistula closure (Figure 2B) at weeks 2–26.
13

14 Certolizumab pegol maintenance did not demonstrate a statistically significant increase in
15 the percentage of patients with at least 50% fistula closure. However, the proportions of
16 patients in the certolizumab pegol maintenance group who had at least 50% fistula closure
17 across the range of time points from weeks 2 to 26 were numerically greater than those
18 receiving placebo (Figure 2A). The decrease in the percentage of patients who had at least
19 50% fistula closure from weeks 8 to 26 in both arms may reflect a lessening of the effect
20 from the 3 induction doses of certolizumab pegol in both the certolizumab pegol and placebo
21 arms. There was a statistically significant increase in the percentage of patients with 100%
22 fistula closure in the certolizumab pegol group compared with patients in the placebo group
23 (Figure 2B). At week 26, 36% (10 of 28) of patients in the certolizumab pegol group had
24 100% fistula closure compared with 17% (5 of 30) of patients in the placebo group ($P =$
25 0.038).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Efficacy: maintenance of fistula closure

46 The differences between certolizumab pegol 400 mg and placebo for the primary endpoint of
47 prespecified definition of fistula closure did not reach statistical significance at week 26.
48

49 However, among patients who achieved the prespecified definition of fistula closure during
50 the study, a numerically higher proportion of patients treated continuously with certolizumab
51 pegol group versus the patients who received induction followed by placebo maintained 50%
52 fistula closure at week 26 (73.3% [11 of 15] vs. 38.5% [5 of 13]; $P = 0.069$) and had 100%
53 closure at week 26 (66.7% [10 of 15] vs. 30.8% [4 of 13]; $P = 0.064$) (Figure 3).
54
55
56
57
58
59
60

Efficacy: CDAI

In the examined subpopulation of 58 randomized patients with open fistulas at baseline, CDAI response and remission rates were higher in the certolizumab pegol–treated patients than in those given placebo (Figure 4). At week 26, 71% of patients in the certolizumab pegol group vs. 33% in the placebo group achieved a CDAI response ($P = 0.005$), and 54% vs. 20% patients were in CDAI remission ($P = 0.026$).

In those patients who achieved the prespecified definition of fistula closure during the study and achieved 100% fistula closure at week 26, CDAI response was observed in 80% (8 of 10) of patients in the certolizumab pegol group vs. 75% (3 of 4) patients in the placebo group. This compares with 67% (12 of 18) vs. 27% (7 of 26) of patients who did not achieve the prespecified definition of fistula closure and 100% closure at week 26. In patients who achieved the prespecified definition of fistula closure during the study and 100% fistula closure at week 26 CDAI remission rates were 60% (6 of 10) in the certolizumab pegol and 50% (2 of 4) in the placebo group. In contrast, CDAI remission rates in patients who did not achieve the prespecified definition of fistula closure during the study and achieved 100% fistula closure at week 26 were 50% (9 of 18) and 15% (4 of 26), in the certolizumab pegol and placebo groups, respectively. The mean decrease from week 0 in CDAI score was 170 points in the certolizumab pegol group ($n = 23$) compared with 131 in the placebo group ($n = 15$) at week 26.

Health-related quality of life

At week 26, patients in the certolizumab pegol group who had open and draining fistulas at week 0 showed a mean change from baseline in total IBDQ scores of 36.7 vs. 20.7 in the placebo group (Figure 5). Mean changes from week 0 to week 26 in IBDQ scores were 39.5 in the certolizumab pegol group and 30.5 in the placebo group.

1
2
3 Of patients who had open and draining fistulas at week 0, mean changes in the IBDQ from
4 week 0 to week 26 were greater in those who received certolizumab pegol than those who
5 received placebo for all four individual domains of the IBDQ: bowel symptoms (11.2 vs. 6.9),
6 systemic symptoms (7.2 vs. 3.8) and emotional (12.6 vs. 6.1) and social function (5.9 vs.
7 3.9), as well as the overall score (34.0 vs. 23.0).
8
9
10
11
12
13
14
15
16

17 Safety

18
19 In the overall population, certolizumab pegol 400 mg q4w was well tolerated, with a safety
20 profile consistent with that of other anti-TNF therapies.¹⁴ The adverse events that occurred in
21 the 58 patients with open and draining fistulas at week 0 are summarized in Table 2. **One**
22 **patient in the certolizumab pegol group had a serious adverse event of a perineal abscess.**
23 **The abscess was of moderate intensity and unlikely related to the study drug. The patient**
24 **underwent surgery and the abscess resolved with sequelae.** The adverse events that
25 occurred in the patients with fistulas were generally similar to those that occurred in the
26 PRECiSE 2 study overall.¹⁴
27
28
29
30
31
32
33
34
35
36
37
38
39

40 DISCUSSION

41
42 The data reported in this study support the efficacy of certolizumab pegol in patients with
43 fistulizing CD. **Although the differences between certolizumab pegol 400 mg and placebo for**
44 **the primary endpoint of prespecified definition of fistula closure did not reach statistical**
45 **significance at week 26,** more patients in the certolizumab pegol 400 mg q4w maintenance
46 group achieved fistula closure compared with the placebo q4w group. **Several reasons may**
47 **account for why the difference between the certolizumab pegol 400 mg and placebo for the**
48 **primary endpoint of prespecified definition of fistula closure did not reach statistical**
49 **significance.** First, the overall sample size of each group was small. Second, 100% fistula
50 closure may have been a better primary endpoint than the protocol-defined outcome for
51
52
53
54
55
56
57
58
59
60

1
2
3 fistula closure. Lastly, the placebo group was not a true representation of a placebo
4
5 response. Patients in the placebo group had received a successful course of induction
6
7 therapy with certolizumab pegol before they had been randomized to placebo maintenance.
8
9
10 In the certolizumab pegol group, 73% of patients maintained at least 50% fistula closure by
11
12 week 26 and 67% maintained 100% closure by week 26. In the placebo group, 39% of
13
14 patients maintained at least 50% fistula closure by week 26 and 31% maintained 100%
15
16 closure by week 26. The findings summarized above demonstrate a generally consistent
17
18 numeric advantage in favor of certolizumab pegol.
19
20
21
22

23 The different definitions of fistula closure and time point of measurement notwithstanding,
24
25 these results are generally similar to those reported for the anti-TNF agents infliximab and
26
27 adalimumab. In ACCENT II, a randomized, controlled study of infliximab in fistulizing CD,
28
29 36% of patients in the infliximab 5 mg/kg q8w maintenance group had a complete absence
30
31 of draining fistulas vs. 19% of patients in the placebo maintenance group ($P = 0.009$) at
32
33 week 54.¹³ At the end of the CHARM study (week 56), 33% (23 of 70) of patients who had
34
35 fistulas at baseline and were randomized to adalimumab (combined results from patients in
36
37 the 40 mg q2w and 40 mg weekly groups) had fistula healing (defined as no drainage, either
38
39 spontaneous or with gentle compression) compared with 13% (6 of 47) in the corresponding
40
41 placebo group ($P < 0.05$).¹¹ The number of smokers in the certolizumab pegol group (8/28)
42
43 was less than in the placebo group (15/30), a difference that could potentially affect the
44
45 primary endpoint, as many,¹⁸⁻²⁰ but not all,²¹⁻²³ studies have shown an unfavourable effect of
46
47 smoking on disease course. In the present study, statistical analyses were not performed for
48
49 differences based on baseline demographic characteristics. However, other studies have
50
51 shown no effect of active smoking on the efficacy of anti-TNF agents in patients with CD.²⁴⁻²⁶
52
53
54
55
56

57 Patients assigned to certolizumab pegol maintained fistula closure and had higher rates of
58
59 CDAI response and remission than patients in the placebo group. In the certolizumab pegol
60
group, 71% of patients achieved clinical response and 54% of patients achieved clinical

1
2
3 remission based on CDAI criteria. However, it should be noted that since fistula is a
4
5 component of the CDAI, the CDAI score does not represent an independent variable.
6
7
8

9
10 In addition to the clinical improvements, certolizumab pegol showed a greater improvement
11
12 on patients' health-related quality of life compared with placebo, as demonstrated by
13
14 improvements in the overall and individual domain scores of the IBDQ. Among the individual
15
16 IBDQ domains, bowel symptoms (11.2 vs. 6.9), systemic symptoms (7.2 vs. 3.8) and
17
18 emotional function (12.6 vs. 6.1) showed the greatest improvement in the certolizumab pegol
19
20 group compared with placebo. Notably, the mean IBDQ score in PRECiSE 2 was 175 at
21
22 week 6. In the present study, which comprised patients with open fistulas at baseline, the
23
24 mean IBDQ score at week 6 was 128, indicating that fistulas are associated with a worse
25
26 health-related quality of life.
27
28
29

30
31 Following stricter and more clinically relevant definitions of fistula closure than those that
32
33 were initially prespecified to examine data from patients with open fistulas in the PRECiSE 2
34
35 study, it was shown that fistula closure is maintained following continuous treatment with
36
37 certolizumab pegol compared with placebo. These data suggest that certolizumab pegol
38
39 maintenance therapy provides fistula closure and other clinical benefits in patients with
40
41 moderate to severe CD and open draining fistulas. (Clinicaltrials.gov identifier:
42
43 NCT00152425).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Felley C, Mottet C, Juillerat P, et al. Fistulizing Crohn's disease. *Digestion*. 2007;76(2):109-112.
2. Schwartz DA, Loftus EV, Jr., Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. *Gastroenterology*. 2002;122(4):875-880.
3. Kamm MA, Ng SC. Perianal fistulizing Crohn's disease: a call to action. *Clin Gastroenterol Hepatol*. 2008;6(1):7-10.
4. Nielsen OH, Rogler G, Hahnloser D, Thomsen OO. Diagnosis and management of fistulizing Crohn's disease. *Nat Clin Pract Gastroenterol Hepatol*. 2009;6(2):92-106.
5. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn's disease. *Gastroenterol Clin North Am*. 2004;33(2):421-xii.
6. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. *Gastroenterology*. 2003;125(5):1508-1530.
7. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. *Inflamm Bowel Dis*. 2009;15(1):17-24.
8. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. *Gastroenterology*. 1982;83(2):383-387.
9. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. *Ann Intern Med*. 1995;123(2):132-142.
10. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. *Clin Gastroenterol Hepatol*. 2008;6(6):644-653.
11. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. *Gut*. 2009;58(7):940-948.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med*. 1999;340(18):1398-1405.
13. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med*. 2004;350(9):876-885.
14. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med*. 2007;357(3):239-250.
15. Best WR, Beckett JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology*. 1976;70(3):439-444.

16. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. *Gastroenterology*. 1994;106(2):287-296.
17. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 1999;28(4):S23-S27.
18. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. *Eur J Gastroenterol Hepatol*. 1996;8(3):225-228.
19. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. *Aliment Pharmacol Ther*. 1999;13(11):1403-1411.
20. Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. *Gut*. 1992;33(6):779-782.
21. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. *Gastroenterology*. 1998;115(2):259-267.
22. Martin G, Heyen F, Dube S. [Factors of recurrence in Crohn disease]. *Ann Chir*. 1994;48(8):685-690.
23. van der HF, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis*. 2009;15(8):1199-1207.
24. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet*. 2008;371(9613):660-667.
25. Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. *Inflamm Bowel Dis*. 2004;10(4):346-351.
26. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. *Am J Gastroenterol*. 2002;97(9):2357-2363.

Declaration of funding interests

This study was funded in full by UCB (Clinicaltrials.gov identifier: NCT00152425). The preparation of this paper was funded in part by UCB. Writing support was provided by Ann P. Tighe, PhD, and Sian Kneller of PPSI (a PAREXEL company) and funded by UCB.

Table 1. Demographic characteristics at screening of patients with open, draining fistulas in the double-blind maintenance phase

	Placebo (n = 30)	Certolizumab pegol 400 mg q4w (n = 28)
Age, y		
Mean \pm standard deviation (s.d.)	37.6 \pm 10.1	37.3 \pm 9.4
Range	21–55	20–54
Gender, male, n (%)	20 (66.7)	14 (50.0)
Duration of disease, y		
Mean \pm s.d.	10.2 \pm 8.9	7.8 \pm 5.9
Median	8.2	6.2
Range	0.4–32.7	1.1–25.8
Current smoker, n (%)	15 (50.0)	8 (28.6)
Crohn's Disease Activity Index (CDAI) score*		
Mean \pm s.d.	317.1 \pm 69.4	299.8 \pm 58.3
Range	215–439	191–442
Location of disease, n (%)		
Terminal ileum	2 (6.7)	5 (17.9)
Colon	10 (33.3)	11 (39.3)
Ileocolon	16 (53.3)	12 (42.9)
Upper gastrointestinal	2 (6.7)	0
Disease behaviour, n (%)		
Inflammatory	5 (16.7)	2 (7.1)
Stricturing	1 (3.3)	2 (7.1)
Penetrating	24 (80.0)	24 (85.7)
Mean number of fistulas per patient		
Mean \pm s.d.	2.0 \pm 1.9	1.6 \pm 0.7
Median	1.0	1.0
Range	1.0–9.0	1.0–3.0
Number of resections, n (%)		
0	19 (63.3)	23 (82.1)
1	6 (20.0)	4 (14.3)
2	2 (6.7)	1 (3.6)
3	2 (6.7)	0
>3	1 (3.3)	0
Fistula type, n (%)		
Anal	28 (93.3)	27 (96.4)
Other	3 (10.0)	1 (3.6)
Prior anti-tumour necrosis factor use		
Yes, n (%)	11 (36.7)	11 (39.3)
Concomitant medication, n (%)		
Corticosteroids (with or without immunosuppressants)	6 (20.0)	5 (17.9)
Immunosuppressants (with or without corticosteroids)	13 (43.3)	17 (60.7)
Corticosteroids and immunosuppressants	5 (16.7)	2 (7.1)
No corticosteroids and no immunosuppressants	16 (53.3)	8 (28.6)

*CDAI scores were subsequently re-calculated based on the Week 0 hematocrit value.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

q4w = every 4 weeks.

For Peer Review

Table 2. Summary of adverse events (AEs) during induction and maintenance treatment with certolizumab pegol or placebo in patients with open, draining fistulas at baseline

AE	Double-blind phase		
	Open-label induction (N = 58)	Placebo (n = 30)	Certolizumab pegol 400 mg q4w (n = 28)
Patients who reported AEs, n (%)	30 (51.7)	24 (80.0)	15 (53.6)
Total number of AEs	54	63	40
AEs occurring at frequency of $\geq 10\%$ in any treatment group, n (%)			
Headache	8 (13.8)	2 (6.7)	1 (3.6)
Arthralgia	0	1 (3.3)	3 (10.7)
Injection site pain	0	3 (10.0)	1 (3.6)
Pyrexia	1 (1.7)	3 (10.0)	0
Patients who reported drug-related AEs, n (%)	6 (10.3)	9 (30.0)	6 (21.4)
Patients in whom AEs led to permanent study drug discontinuation, n (%)	0	4 (13.3)	1 (3.6)
Patients who reported serious AEs, n (%)	1 (1.7)	3 (10.0)	1 (3.6)
Total number of serious AEs	1	4	1
Patients who reported infections, n (%)	12 (20.7)	7 (23.3)	9 (32.1)
Patients who reported serious infections, n (%)	0	0	1 (3.6)*
Patients who reported injection-site pain, n (%)	10 (1.7)	1 (0.0)	0 (0.0)
Patients who died, n (%)	0	0	0

*Perineal abscess.

q4w = every 4 weeks.

1
2
3 Figure 1. Patient disposition.
4
5
6


7
8 Figure 2. Percentage of patients with (A) at least 50% fistula closure and (B) 100% fistula
9
10 closure at weeks 2–26. Error bars represent 95% confidence intervals for percentage
11
12 response. q4w = every 4 weeks.
13
14
15

16
17 Figure 3. Fistula closure based on prespecified definition in the PRECiSE 2 study (closure of
18
19 $\geq 50\%$ of fistulas at any two consecutive post-baseline visits ≥ 3 weeks apart) at week 26.
20
21 Error bars represent 95% confidence intervals for percentage frequency. q4w = every 4
22
23 weeks.
24
25
26

27
28 Figure 4. Crohn's Disease Activity Index (CDAI) response (≥ 100 point decrease from
29
30 baseline) and remission (CDAI ≤ 150 points) at week 26. Error bars represent 95%
31
32 confidence intervals for percentage response. q4w = every 4 weeks.
33
34
35

36
37 Figure 5. Mean change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)
38
39 score at week 26 (last observation carried forward).* Error bars represent 95% confidence
40
41 intervals for mean change. q4w = every 4 weeks.
42
43
44

45
46 *One patient did not provide post-baseline data; thus last observation carried forward analysis was
47
48 not applied.
49
50
51
52
53
54
55
56
57
58
59
60





*More than one reason could be specified. q4w = every 4 weeks.

254x190mm (96 x 96 DPI)


Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






UCBPH 101330 M08 M15 MAND SY





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



UCBPH 101330 M08 M15 MAND SY

1
2
3
4 **Statement of Interests**
5

6 ***Authors' declaration of personal interests***
7
8
9

10 **S. Schreiber** has served as a speaker, a consultant and/or an advisory board member for
11 Abbot Laboratories, BayerSchering, Centocor, Dr. Falk Pharma, Essex/Schering Plough,
12 Ferring, Genentech, Glaxo-SmithKline, Novartis, Novo-Nordisk, Pfizer, Schering-Plough and
13 its subsidiary Essex Pharma., UCB and owns stocks and shares in Conaris Research
14 Institute.
15
16
17
18
19

20
21
22
23 **I.C. Lawrance** has served as a speaker, consultant and an advisory board member for
24 Abbott Australasia, Schering-Plough, Janssen-Cilag Pharmaceuticals, Pharmatel Fresenius
25 Kabi and has received research funding from Abbott Australasia.
26
27
28
29

30
31
32 **O.Ø. Thomsen** has served as a consultant and an advisory board member for UCB,
33 Zealand Pharma and as a speaker for Schering-Plough and UCB.
34
35
36
37

38 **S.B. Hanauer** has served as a consultant and advisory board member for Abbot
39 Laboratories, AstraZeneca, Bristol Myers Squibb, Centocor, Elan Pharmaceuticals, Ferring
40 Pharmaceuticals, Genentech, GlaxoSmithKline, Millenium Pharmaceuticals, Proctor and
41 Gamble, Prometheus, Salix, Shire, UCB and has received research funding from Abbot
42 Laboratories, Bristol Myers Squibb, Centocor, Elan Pharmaceuticals, Ferring
43 Pharmaceuticals, Genentech, Proctor and Gamble, Prometheus, Salix, Shire and UCB.
44
45
46
47
48
49
50
51

52
53 **R. Bloomfield** is an employee of UCB.
54
55
56
57

58 **W.J. Sandborn** has served as consultant and advisory board member for Abbott
59 Laboratories (fees paid to Mayo), ActoGenix, AGI Therapeutics, Albireo, Alfa Wassermann,
60

1
2
3 AM-Pharma, Amgen, Anaphore, Astellas Pharma, Athersys, Atlantic Healthcare Limited,
4
5 Axcan Pharma, BioBalance Corporation, Bristol Meyers Squibb (fees paid to Mayo), Celek
6
7 Pharmaceuticals, Celgene, Cellerix, CentocorOrthoBiotech (fees paid to Mayo),
8
9 Chemocentryx, CoMentis, Cosmo Technologies, Cytokine Pharmasciences, Eagle
10
11 Pharmaceuticals, Eisai Medical Research, Elan Pharmceuticls (fees paid to Mayo), Eli Lilly,
12
13 Enteromedics, Ferring Pharmaceuticals, Flexion Therapeutics, Funxional Therapeutics
14
15 Limited, Genentech (fees paid to Mayo), Given Imaging, GlaxoSmithKline, KaloBios
16
17 Pharmaceuticals, Merck Research Laboratories, Merck Serono, Novo Nordisk, Pfizer Inc
18
19 (fees paid to Mayo), Procter & Gamble (fees paid to Mayo), Purgensis Technologies,
20
21 Regeneron Pharmaceuticals, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus,
22
23 Schering Plough Corporation, Shire Pharmaceuticals (fees paid to Mayo), Sigmoid Pharma,
24
25 Sitrtis Pharmaceuticals, SLA Pharma, Takeda (fees paid to Mayo), Tillotts Pharma, UCB
26
27 (fees paid to Mayo), Vascular Biogenics, Viamet Pharmaceuticals and Wyeth and has
28
29 received research funding from Abbott Laboratories, Bristol Meyers Squibb,
30
31 CentocorOrthoBiotech, Genentech, Millennium Pharmaceuticals, Novartis, Pfizer Inc, Shire
32
33 Pharmaceuticals, UCB, Warner Chilcott (previously Procter & Gamble).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Declaration of funding interests

This study was funded in full by UCB (Clinicaltrials.gov identifier: NCT00152425). The preparation of this paper was funded in part by UCB. Writing support was provided by Ann P. Tighe, PhD, and Sian Kneller of PPSI (a PAREXEL company) and funded by UCB.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60